Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(5)

MIXED(4)

BIOLOGICAL(1)

ahon-pharmaceutical-co-ltd

Letrozole 2.5mg

1 trial

phase_1_2

ahon-pharmaceutical-co-ltd

EOC202

1 trial

phase_1

taizhou-eoc-pharma-co-ltd

Personalized treatment guided by mini-PDX and RNA sequencing

+2 more interventions

10 unique interventions3 categories

Analytics

Trial Phases

Phase 12

Phase 22

Trial Status

Completed1

Other2

Role Distribution

Principal Investigator3

PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT04745975Phase 2Unknown

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

PrincipalinvestigatorStart date: 2021-02-01

NCT04488107Phase 1/2Unknown

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Breast Neoplasms

PrincipalinvestigatorStart date: 2019-02-14

NCT03600090Phase 1Completed

Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

Solid Tumor, Adult

PrincipalinvestigatorStart date: 2018-10-16

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Breast Neoplasms1 Solid Tumor, Adult1 Triple Negative Breast Neoplasms1

Affiliations

Fudan University

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mothaffar Rimawi, MD

Baylor College of Medicine

8 trials

Shared therapeutic areas:

Breast NeoplasmsTriple Negative Breast Neoplasms

Similarity Score20%

Kathy Miller, MD

Indiana University

13 trials

Shared therapeutic areas:

Breast NeoplasmsTriple Negative Breast Neoplasms

Similarity Score20%

Norman Wolmark, MD

NSABP Foundation Inc

54 trials

Shared therapeutic areas:

Breast NeoplasmsTriple Negative Breast Neoplasms

Similarity Score20%

Jean-Philippe Aussel

Sanofi

9 trials

Shared therapeutic areas:

Breast Neoplasms

Similarity Score10%

Zhong-yu Yuan, M.D.

Sun Yat-sen University

9 trials

Shared therapeutic areas:

Triple Negative Breast Neoplasms

Similarity Score10%

Priyanka Sharma, MD

University of Kansas Medical Center

8 trials

Shared therapeutic areas:

Triple Negative Breast Neoplasms

Similarity Score10%

Mark Jones, MD

Incyte Corporation

8 trials

Shared therapeutic areas:

Triple Negative Breast Neoplasms

Similarity Score10%

Soo Chin Lee

National University Hospital, Singapore

15 trials

Shared therapeutic areas:

Triple Negative Breast Neoplasms

Similarity Score10%

Lily Hu

DualityBio Inc.

8 trials

Shared therapeutic areas:

Solid Tumor, Adult

Similarity Score10%

Pamela Munster, MD

University of California, San Francisco

8 trials

Shared therapeutic areas:

Breast Neoplasms

Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT04745975Phase 2PrincipalInvestigator

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

Unknown

NCT04488107Phase 1/2PrincipalInvestigator

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Breast Neoplasms

Unknown

NCT03600090Phase 1PrincipalInvestigator

Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer

Solid Tumor, Adult

Completed

All 3 trials loaded